Showing papers on "Chebulinic acid published in 2018"
TL;DR: It is shown that CA, CI and GA can be a potential pharmacological agents in the management of DR and NV-AMD because of their anti-TNFα activity.
57 citations
TL;DR: Chebulinic acid is not only a critical component of the anticancer activities of triphala but also a promising natural multi-target antitumour agent with therapeutic potential.
Abstract: Triphala is an Ayurvedic rasayana formulation reputed for its antitumour activities, and chebulinic acid and chebulagic acid, along with other phenolic acids, have been proposed to be responsible for its effects. In this study, the anti-proliferative activities of these agents were evaluated in colorectal carcinoma cell lines with three phenotypes exposed to several batches of triphala samples with different quantities of chebulinic acid and chebulagic acid. The pro-apoptotic and anti-migratory activities and the probable antitumour mechanisms of the more potent anti-proliferative phytochemical were also investigated. The results demonstrated that chebulinic acid, which exerts potent anti-proliferative, pro-apoptotic and anti-migratory effects, is a key molecule for maintaining the antitumour efficacy of triphala. The antitumour mechanism of chebulinic acid is probably related to the PI3K/AKT and MAPK/ERK pathways. Chebulinic acid is not only a critical component of the anticancer activities of triphala but also a promising natural multi-target antitumour agent with therapeutic potential.
20 citations
Patent•
28 Mar 2018
TL;DR: In this paper, an antimicrobial composition comprising a natural plant extract, which is free from toxicity, exhibits an excellent antimicrobial effect, can be a substitute for conventional synthetic preservatives, and comprises cavacrol and chebulinic acid as active ingredients.
Abstract: The present invention relates to an antimicrobial composition comprising a natural plant extract, which is free from toxicity, exhibits an excellent antimicrobial effect, can be a substitute for conventional synthetic preservatives, and comprises cavacrol and chebulinic acid as active ingredients. The present invention also relates to a cosmetic composition containing the antimicrobial composition.
2 citations
Patent•
05 Jan 2018
TL;DR: In this article, a method for the preparation of a cell synergistic compound consisting of the following steps is presented: preparing glycyrrhetinic acid with the concentration of 89.04 [mu]mol/L to 96.8 [m]mol/L; preparing ophiopogonpolysaccharide with a concentration of 800 [m]-g/mL, atractylodes macrocephalaon polysaccharides with a density of 800 m/m/m and saposhnikovia divaricata polysacchide with
Abstract: The invention belongs to the technical field of medicine and discloses a preparation method of a cell synergistic compound. The preparation method of the cell synergistic compound comprises the following steps: preparing glycyrrhetinic acid with the concentration of 89.04 [mu]mol/L to 96.8 [mu]mol/L; preparing ophiopogonpolysaccharide with the concentration of 800 [mu]g/mL, atractylodes macrocephalaon polysaccharide with the concentration of 800 [mu]g/mL and saposhnikovia divaricata polysaccharide with the concentration of 800 [mu]g/mL; preparing chebulinic acid with the concentration of 0.04mmol/L to 0.09 mmol/L and tellimagrandin I with the concentration of 0.04 mmol/L to 0.09 mmol/L; mixing and adding into a serum-free culture medium to perform cultivation. The glycyrrhetinic acid hasin vitro proliferation and inhibition effects on a myelogenous leukemia cell line K562, the change of cell cycle caused by the glycyrrhetinic acid is analyzed, and the possible anti-cancer mechanism is discussed; three kinds of traditional Chinese herbal medicine polysaccharide of radix ophiopogonis, bighead atractylodes rhizome and radices sileris are adopted, and the influence of crude ophiopogonpolysaccharide POJ on the proliferation and inhibition effect of leukemia cell K562 cells is detected by an MTT method.
1 citations
Patent•
08 Nov 2018
TL;DR: A composition or medicament including an extract of Terminalia ferdinadiana (T. ferdinandiana) as an antimicrobial or antibacterial agent for use in treating microbiasl/bacterial infection in humans or animals, preferably B. anthracis or C. perfringens or Giardia infection as discussed by the authors.
Abstract: A composition or medicament including an extract of Terminalia ferdinadiana (T. ferdinandiana) as an antimicrobial or antibacterial agent for use in treating microbiasl/bacterial infection in humans or animals, preferably B. anthracis or C. perfringens or Giardia infection. The extract may be or include T. ferdinandiana leaf extract. The extract can include at least one antioxidant, such as ellagic acid or trimethyl ellagic acid, and can include at least one tannin and/or at least one flavone and/or chebulic acid, corilagen, chebulinic acid or chebulagic acid and/or at least one flavone or flavinoid.